Northeast Investment Management Sells 5,405 Shares of Abbott Laboratories $ABT

Northeast Investment Management decreased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 6.0% during the first quarter, HoldingsChannel reports. The firm owned 85,260 shares of the healthcare product maker’s stock after selling 5,405 shares during the period. Northeast Investment Management’s holdings in Abbott Laboratories were worth $8,754,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ABT. Nia Impact Advisors LLC boosted its position in Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after acquiring an additional 79 shares in the last quarter. American National Bank of Texas boosted its position in Abbott Laboratories by 2.4% during the fourth quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock valued at $427,000 after purchasing an additional 79 shares in the last quarter. Park Place Capital Corp lifted its position in shares of Abbott Laboratories by 11.0% during the fourth quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock valued at $102,000 after buying an additional 81 shares during the last quarter. Lantern Wealth Advisors LLC boosted its holdings in shares of Abbott Laboratories by 1.7% in the 3rd quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock valued at $674,000 after buying an additional 84 shares in the last quarter. Finally, Clayton Financial Group LLC grew its position in shares of Abbott Laboratories by 1.4% in the 4th quarter. Clayton Financial Group LLC now owns 6,217 shares of the healthcare product maker’s stock worth $779,000 after buying an additional 84 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott announced a global licensing agreement with ALZpath to develop a blood-based Alzheimer’s diagnostic test for its Alinity ci-series systems, opening a potential new growth avenue in high-demand neurology testing. Article: ALZpath signs licensing deal with Abbott to develop Alzheimer’s blood test
• Positive Sentiment: Recent commentary highlighted Abbott’s expanding diabetes franchise, especially FreeStyle Libre, and said the stock looks attractive after sector rotation pushed it lower, with one note calling it a “Buy” on growth and catalyst potential. Article: Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy
• Positive Sentiment: Multiple articles pointed to strong investor sentiment, including bullish hedge fund positioning and estimates of roughly 31% upside, suggesting Wall Street still views Abbott as a quality large-cap healthcare name. Article: How Does Wall Street View Abbott Laboratories (ABT)’s Outlook?
• Positive Sentiment: Coverage also emphasized Abbott’s dividend record, four-segment business model, and recession-resistant cash flow, which can support the stock during periods of market rotation away from defensive names. Article: 3 Dividend Aristocrat Stocks with 20%+ Upside — June 25, 2026
• Neutral Sentiment: Abbott said it will host its second-quarter earnings conference call on July 16, keeping attention on upcoming results and guidance but not changing fundamentals yet. Article: Abbott hosts conference call for second-quarter earnings
• Neutral Sentiment: Other recent pieces cited emerging-market momentum in established pharmaceuticals and new sensor distribution in Europe, adding to the bullish narrative without being major near-term stock drivers. Article: How Are Emerging Markets Supporting Abbott’s EPD Momentum?

Analyst Ratings Changes

A number of research firms recently commented on ABT. The Goldman Sachs Group decreased their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Leerink Partners reduced their price target on Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a research report on Tuesday, April 21st. Piper Sandler reiterated an “overweight” rating and set a $115.00 price objective on shares of Abbott Laboratories in a report on Monday. TD Cowen dropped their target price on Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Royal Bank Of Canada reduced their target price on Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.30.

Insider Buying and Selling

In other Abbott Laboratories news, Director Daniel J. Starks purchased 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 27th. The shares were bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The shares were acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the completion of the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Price Performance

Shares of ABT opened at $93.12 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The company’s fifty day moving average price is $89.23 and its 200-day moving average price is $105.46. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.54. The firm has a market capitalization of $162.19 billion, a PE ratio of 26.08, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. During the same quarter last year, the business posted $1.09 EPS. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, equities research analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.7%. Abbott Laboratories’s payout ratio is 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.